Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M K Parmar

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Cancer|February 1, 1993
Adjuvant therapy in prostatic cancerP H Smith, M K Parmar
International Journal of Technology Assessment in Health Care|January 1, 1996
Bias in the analysis and reporting of randomized controlled trialsL A Stewart, M K Parmar
Lancet (London, England)|February 13, 1993
Meta-analysis of the literature or of individual patient data: is there a difference?L A Stewart, M K Parmar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2001
Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancerC N Sternberg, M K Parmar
Statistics in Medicine|January 28, 1999
Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsM K Parmar, V Torri, L Stewart
British Journal of Cancer|December 4, 1998
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidenceJ Sandercock, M K Parmar, V Torri
British Journal of Urology|May 1, 1995
The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practiceJ Reading, R R Hall, M K Parmar
Journal of the National Cancer Institute|November 20, 1996
Assessing whether to perform a confirmatory randomized clinical trialM K Parmar, R S Ungerleider, R Simon
Statistics in Medicine|June 30, 1997
Tutorial in biostatistics Bayesian data monitoring in clinical trialsP M Fayers, D Ashby, M K Parmar
Statistics in Medicine|July 15, 1994
The CHART trials: Bayesian design and monitoring in practice. CHART Steering CommitteeM K Parmar, D J Spiegelhalter, L S Freedman
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Cancer|February 1, 1993
Adjuvant therapy in prostatic cancerP H Smith, M K Parmar
International Journal of Technology Assessment in Health Care|January 1, 1996
Bias in the analysis and reporting of randomized controlled trialsL A Stewart, M K Parmar
Lancet (London, England)|February 13, 1993
Meta-analysis of the literature or of individual patient data: is there a difference?L A Stewart, M K Parmar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2001
Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancerC N Sternberg, M K Parmar
Statistics in Medicine|January 28, 1999
Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsM K Parmar, V Torri, L Stewart
British Journal of Cancer|December 4, 1998
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidenceJ Sandercock, M K Parmar, V Torri
British Journal of Urology|May 1, 1995
The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practiceJ Reading, R R Hall, M K Parmar
Journal of the National Cancer Institute|November 20, 1996
Assessing whether to perform a confirmatory randomized clinical trialM K Parmar, R S Ungerleider, R Simon
Statistics in Medicine|June 30, 1997
Tutorial in biostatistics Bayesian data monitoring in clinical trialsP M Fayers, D Ashby, M K Parmar
Statistics in Medicine|July 15, 1994
The CHART trials: Bayesian design and monitoring in practice. CHART Steering CommitteeM K Parmar, D J Spiegelhalter, L S Freedman
Pageof 8